Abstract
For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95-96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79-84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months.
Keywords: COVID-19; Omicron variant; Slovenia; mRNA vaccines; severe acute respiratory infection (SARI); surveillance; vaccine effectiveness.
All Keywords
【저자키워드】 COVID-19, mRNA vaccines, Surveillance, Omicron variant, vaccine effectiveness, Slovenia, severe acute respiratory infection (SARI), 【초록키워드】 SARS-CoV-2, Vaccine, mRNA vaccine, variant, omicron, mRNA vaccines, respiratory infection, mRNA, Effectiveness, Acute respiratory infection, Omicron variant, age, Slovenia, 95% CI, individual, surveillance data, doses, SARI, 【제목키워드】 mRNA vaccine, variant, omicron, Effectiveness, hospitalisation,
【저자키워드】 COVID-19, mRNA vaccines, Surveillance, Omicron variant, vaccine effectiveness, Slovenia, severe acute respiratory infection (SARI), 【초록키워드】 SARS-CoV-2, Vaccine, mRNA vaccine, variant, omicron, mRNA vaccines, respiratory infection, mRNA, Effectiveness, Acute respiratory infection, Omicron variant, age, Slovenia, 95% CI, individual, surveillance data, doses, SARI, 【제목키워드】 mRNA vaccine, variant, omicron, Effectiveness, hospitalisation,
{{{ 추상적인 }}}
2022년 2월부터 3월까지 슬로베니아에서 SARS-CoV-2 오미크론 변이가 우세한 기간 동안 감시 데이터를 사용하여 중증 급성 호흡기 감염(SARI) COVID-19에 대한 mRNA 백신 효과(VE)를 추정했습니다. 65세 이상 개인으로 구성된 가장 취약한 연령 그룹에서 SARI COVID-19에 대한 VE는 3회 접종을 받은 사람들의 95%(95% CI: 95-96%)로 82%(95% CI: 79-84%) 두 번 접종한 사람들의 경우. 이러한 보호 수준은 최소 6개월 동안 유지되었습니다.
{{ 키워드: }} 코로나19; 오미크론 변이체; 슬로베니아; mRNA 백신; 중증 급성 호흡기 감염(SARI); 감시; 백신 효과.